Related Experiment Video
Updated: Jul 16, 2025

Macrophage Cholesterol Depletion and Its Effect on the Phagocytosis of Cryptococcus neoformans
Published on: December 19, 2014
Glucocorticoids, COVID-19 and Cryptococcosis.
Wanessa Maria Dos Santos1, Alexandre Paula Rogerio1
1Departamento de Biomedicina, Laboratory of Experimental Immunopharmacology, Universidade Federal of Triângulo Mineiro, Rua Manoel Carlos, 162. 38025-380, Uberaba, MG, Brazil.
Glucocorticoid treatment for COVID-19 can increase the risk of dangerous Cryptococcus infections. Distinguishing between COVID-19 and cryptococcosis is challenging due to similar symptoms.
Area of Science:
- Infectious Diseases
- Pulmonology
- Immunology
Background:
- Cryptococcus neoformans and C. gattii can cause asymptomatic or severe pneumonitis, particularly in immunocompromised individuals.
- COVID-19 presents with varied symptoms, including pneumonitis, and glucocorticoids are used for severe cases.
- Glucocorticoid therapy, while beneficial for COVID-19, elevates the risk of opportunistic infections like cryptococcosis.
Discussion:
- Patients with severe COVID-19 pneumonia treated with glucocorticoids have developed fatal cryptococcal infections.
- Immunomodulatory therapy for COVID-19 may trigger acute infections or reactivation of Cryptococcus species.
- Pulmonary cryptococcosis symptoms mimic COVID-19, complicating diagnosis and treatment decisions.
Key Insights:
- Glucocorticoids used in COVID-19 treatment pose a significant risk for cryptococcal coinfection or superinfection.
- The immunomodulatory effects of glucocorticoids can predispose COVID-19 patients to Cryptococcus reactivation.
- Clinical presentation overlap between COVID-19 and pulmonary cryptococcosis necessitates careful differential diagnosis.
Outlook:
- Further research is needed to understand the interplay between COVID-19, glucocorticoid therapy, and Cryptococcus infections.
- Developing diagnostic strategies to differentiate COVID-19 from cryptococcosis in patients on glucocorticoids is crucial.
- Investigating alternative or adjunctive therapies to mitigate Cryptococcus risk in glucocorticoid-treated COVID-19 patients is warranted.
Related Concept Videos
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Overview of Carbohydrate Metabolism
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...

